ChronoScale Holdings completed the sale of its Ekso Bionics subsidiary on September 30, 2026. Concurrently, the company announced expanded agreements with existing and new AI infrastructure customers, projecting a total contracted annualized run-rate revenue of $1 billion by calendar Q3 2027. The divestiture allows ChronoScale to focus resources on its core accelerated compute business. Additionally, Jason C. Jones was terminated as Chief Operating Officer of Ekso in connection with the transaction and received severance benefits including a lump-sum payment of $243,750 and nine months of COBRA coverage. The company also filed a Withdrawal of Designation for Series B Convertible Preferred Stock, which had no shares outstanding. ChronoScale operates in the artificial intelligence infrastructure sector, providing scalable GPU-based accelerated compute platforms.
